Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market
Category: #health  By Mateen Dalal  Date: 2019-09-21
  • share
  • Twitter
  • Facebook
  • LinkedIn

Lineage Cell Therapeutics’ Renevia bags CE Mark Approval for EU market

Aesthetic medicine is increasingly being used for the treatment of physical impairments such as skin discoloration, excessive fat, scars, skin laxity, wrinkles, cellulite, and liver spots. Customer are seen demanding for resurfacing and non-invasive skin tightening treatments for the past few years which is expected to rise exponentially in the coming years.

Advancements in this field were made recently when Lineage Cell Therapeutics, Inc., a biotechnology company that focuses on innovating novel cell therapies for untreated medical needs, announced that Renevia®, the biotech’s facial aesthetics drug, achieved a Conformité Européenne (CE) Mark.

As per reports, Renevia has obtained a Class III classification with a planned use in adults as a resorbable matrix for generating autologous adipose tissue preparations to augment and restore facial volume after enduring subcutaneous fat loss for the therapy of facial lipoatrophy.

Apparently, the CE Mark will offer the company the right to distribute and market Renevia all over the European Union (EU) and in all other nations that identify the CE Mark.

Speaking on the announcement, Brian M. Culley, Chief Executive Officer, Lineage, said that gaining CE Mark approval for the drug was a significant corporate achievement that validates the company’s capability to produce positive data from clinical studies and direct a supervisory application from a promising registration and review process.

He added that, following the approval, its Board of Directors have allowed it to select a European representative for business development to negotiate and evaluate the partnership prospects for Renevia.

In light of its efforts on developing its three clinical-stage programs for cell therapy, Lineage is also seeking an external collaborator that has the commercial competences and enough knowledge to promote Renevia in the European market, which would provide the biotech firm enough funds to support its novel cell therapy programs.

Reportedly, the company had made headlines earlier when it finally closed its former acquisition of Asterias Biotherapeutics, Inc. As per reports, the company had completed its acquisition through a merger which led Asterias to become a fully-owned subsidiary of the company with all its operations combined with Lineage.

Source Credit: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-receives-ce-mark-approval-reneviar

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...

Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint
Eli Lilly’s Phase 3 SEQUOIA trial fails to meet primary endpoint
By Mateen Dalal

Metastatic pancreatic cancer (MPC) is one of the most fatal cancers in the world. Pancreatic cancer is slated to be the third leading cause of cancer death in the U.S. and is expected to become the second leading cause of cancer-related death over th...

Replimune gives an update on RP1 Clinical Development Program in CSCC
Replimune gives an update on RP1 Clinical Development Program in CSCC
By Mateen Dalal

Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer caused because of the uncontrolled growth of abnormal squamous cells. Currently, Libtayo is the only approved treatment in the Brazil and United States, and condit...